From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
  • US: C (Risk not ruled out)
Routes of
oral, intravenous, intramuscular, subcutaneous
Legal status
Legal status
Pharmacokinetic data
Protein binding 40%
Biological half-life 11-16 hours
CAS Number 77-07-6
ATC code none
PubChem CID 5359272
DrugBank APRD00764
Chemical data
Formula C17H23NO
Molar mass 257.371 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Physical data
Melting point 23 °C (73 °F)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Levorphanol (Levo-Dromoran) is an opioid medication used to treat severe pain. It is the laevorotary stereoisomer of the synthetic morphinan (Dromoran) and a pure opioid agonist, first described in Germany in 1946 as an orally active morphine-like analgesic. Morphinan is the parent drug and prototype of a large series of opioid and/or NMDA antagonists and opioid agonists used in medicine including nalbuphine, butorphanol, dextromethorphan, and others.

Levorphanol labeled with tritium was used in the research which led to the discovery of opioid receptors in the human nervous system, including the first study published in 1971.[1]

Levorphanol has the same properties as morphine with respect to the potential for habituation, tolerance, physical dependence and withdrawal syndrome. It is 4 to 8 times as potent as morphine and has a longer half-life. Approximately 30 mg of oral morphine is roughly equianalgesic to 4 mg of oral levorphanol.[2] The laevo isomer is the source of the narcotic properties of the racemic drug Dromoran, but the dextro isomers are also useful in medicine: in addition to acting on sigma receptors, the O-methyl derivative of its dextrorotary isomer, dextromethorphan, acts as an NMDA receptor antagonist.[3] Oral doses of levorphanol come in 2 mg and 4 mg strengths or subcutaneous injection every 6 to 8 hours.

Levorphanol has affinity to μ, κ, and δ opioid receptors, but lacks complete cross-tolerance with morphine. The duration of action is generally long compared to other comparable analgesics, and varies from 4 hours to as much as 15 hours. For this reason levorphanol is useful in palliation of chronic pain and similar conditions. Levorphanol has an oral to parenteral effectiveness ratio of 2:1, one of the most favourable of the strong narcotics. Its NMDA actions, similar to those of the phenylheptylamine open-chain narcotics such as methadone and ketobemidone, make levorphanol useful for types of pain that other analgesics may not be as effective against; levorphanol's sigma receptor, SNRI properties make it even more useful particularly for neuropathic pain.[4]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

pl:Leworfanol sv:Levorfanol
  1. opioid receptors
  2. www.globalrph.com/narcoticonv.htm
  3. Brookoff D. Hospital Practice. 2000;35:45-59.
  4. Prommer E. Levorphanol: the forgotten opioid. Supportive Care in Cancer. 2007 Mar;15(3):259-64. PMID 17039381